SANA BIOTECHNOLOGY INC (SANA) Fundamental Analysis & Valuation

NASDAQ:SANA • US7995661045

Current stock price

3.36 USD
+0.27 (+8.74%)
At close:
3.2791 USD
-0.08 (-2.41%)
After Hours:

This SANA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. SANA Profitability Analysis

1.1 Basic Checks

  • SANA had negative earnings in the past year.
  • In the past year SANA has reported a negative cash flow from operations.
  • SANA had negative earnings in each of the past 5 years.
  • SANA had a negative operating cash flow in each of the past 5 years.
SANA Yearly Net Income VS EBIT VS OCF VS FCFSANA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

  • SANA has a Return On Assets (-53.83%) which is comparable to the rest of the industry.
  • SANA has a Return On Equity (-120.02%) which is in line with its industry peers.
Industry RankSector Rank
ROA -53.83%
ROE -120.02%
ROIC N/A
ROA(3y)-45.37%
ROA(5y)-41.34%
ROE(3y)-86.33%
ROE(5y)-74.79%
ROIC(3y)N/A
ROIC(5y)N/A
SANA Yearly ROA, ROE, ROICSANA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for SANA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SANA Yearly Profit, Operating, Gross MarginsSANA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. SANA Health Analysis

2.1 Basic Checks

  • SANA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SANA Yearly Shares OutstandingSANA Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
SANA Yearly Total Debt VS Total AssetsSANA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

  • SANA has an Altman-Z score of -4.65. This is a bad value and indicates that SANA is not financially healthy and even has some risk of bankruptcy.
  • SANA has a Altman-Z score of -4.65. This is in the lower half of the industry: SANA underperforms 62.16% of its industry peers.
  • SANA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.65
ROIC/WACCN/A
WACCN/A
SANA Yearly LT Debt VS Equity VS FCFSANA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 4.55 indicates that SANA has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 4.55, SANA is in line with its industry, outperforming 52.70% of the companies in the same industry.
  • A Quick Ratio of 4.55 indicates that SANA has no problem at all paying its short term obligations.
  • The Quick ratio of SANA (4.55) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.55
Quick Ratio 4.55
SANA Yearly Current Assets VS Current LiabilitesSANA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. SANA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 31.90% over the past year.
EPS 1Y (TTM)31.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 4.26% on average over the next years.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y27.74%
EPS Next 2Y10.63%
EPS Next 3Y4.11%
EPS Next 5Y4.26%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SANA Yearly Revenue VS EstimatesSANA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2029 2030 2032 5M 10M 15M 20M 25M
SANA Yearly EPS VS EstimatesSANA Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -1 -2 -3 -4 -5

More info and screens

Find the best growth stocksShow best growing peers

0

4. SANA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for SANA. In the last year negative earnings were reported.
  • Also next year SANA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SANA Price Earnings VS Forward Price EarningsSANA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SANA Per share dataSANA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.63%
EPS Next 3Y4.11%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SANA Dividend Analysis

5.1 Amount

  • SANA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SANA Fundamentals: All Metrics, Ratios and Statistics

SANA BIOTECHNOLOGY INC

NASDAQ:SANA (3/13/2026, 8:00:02 PM)

After market: 3.2791 -0.08 (-2.41%)

3.36

+0.27 (+8.74%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-03
Earnings (Next)05-06
Inst Owners78.05%
Inst Owner Change-5.2%
Ins Owners6.76%
Ins Owner Change0.13%
Market Cap895.00M
Revenue(TTM)N/A
Net Income(TTM)-234.41M
Analysts85.33
Price Target8.33 (147.92%)
Short Float %15.04%
Short Ratio14.86
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)6.63%
Min EPS beat(2)0.47%
Max EPS beat(2)12.79%
EPS beat(4)4
Avg EPS beat(4)8.15%
Min EPS beat(4)0.47%
Max EPS beat(4)12.79%
EPS beat(8)6
Avg EPS beat(8)0.67%
EPS beat(12)9
Avg EPS beat(12)8.96%
EPS beat(16)12
Avg EPS beat(16)9.09%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-4.72%
EPS NQ rev (1m)0%
EPS NQ rev (3m)2.1%
EPS NY rev (1m)0%
EPS NY rev (3m)0.33%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.58
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.79
EYN/A
EPS(NY)-0.57
Fwd EYN/A
FCF(TTM)-0.6
FCFYN/A
OCF(TTM)-0.59
OCFYN/A
SpS0
BVpS0.73
TBVpS-0.02
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -53.83%
ROE -120.02%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-45.37%
ROA(5y)-41.34%
ROE(3y)-86.33%
ROE(5y)-74.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 3.26%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.55
Quick Ratio 4.55
Altman-Z -4.65
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)135.8%
Cap/Depr(5y)216.07%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)31.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y27.74%
EPS Next 2Y10.63%
EPS Next 3Y4.11%
EPS Next 5Y4.26%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y36.46%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year26.46%
EBIT Next 3Y6.62%
EBIT Next 5YN/A
FCF growth 1Y44.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y42.98%
OCF growth 3YN/A
OCF growth 5YN/A

SANA BIOTECHNOLOGY INC / SANA Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for SANA BIOTECHNOLOGY INC?

ChartMill assigns a fundamental rating of 2 / 10 to SANA.


What is the valuation status for SANA stock?

ChartMill assigns a valuation rating of 0 / 10 to SANA BIOTECHNOLOGY INC (SANA). This can be considered as Overvalued.


Can you provide the profitability details for SANA BIOTECHNOLOGY INC?

SANA BIOTECHNOLOGY INC (SANA) has a profitability rating of 1 / 10.